Related Experiment Video
Updated: May 18, 2026
15:01
Quantitative, Real-time Analysis of Base Excision Repair Activity in Cell Lysates Utilizing Lesion-specific Molecular Beacons
Published on: August 6, 2012
Purification and specific assays for measuring APE-1 endonuclease activity
Adrian Esqueda1, Mohammed Z Mohammed, Srinivasan Madhusudan
1Laboratory of Molecular Oncology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, UK.
Methods in Molecular Biology (Clifton, N.J.)
|September 8, 2012
Summary
Human apurinic/apyrimidinic endonuclease-1 (APE-1) is crucial for DNA repair and genomic stability. Inhibiting APE-1 may sensitize cancer cells to chemotherapy, making APE-1 inhibitors valuable for drug development.
Area of Science:
- Molecular Biology
- Biochemistry
- Genetics
Background:
- Human apurinic/apyrimidinic endonuclease-1 (APE-1) is vital for base excision repair and maintaining genomic stability.
- Cancer cells can develop resistance to DNA-damaging agents through the upregulation of DNA repair enzymes like APE-1.
- APE-1 is implicated in cancer progression and drug resistance, making it a target for therapeutic intervention.
Purpose of the Study:
- To describe protocols for APE-1 purification.
- To develop specific assays for APE-1 endonuclease activity.
- To facilitate the identification and validation of APE-1 inhibitors for cancer therapy.
Main Methods:
- Purification of human APE-1 protein.
- Development of high-throughput screening assays for APE-1 endonuclease activity.
- Design of counterscreens to validate inhibitor selectivity.
Main Results:
- Established protocols for obtaining purified APE-1.
- Developed specific and validated assays for measuring APE-1 endonuclease activity.
- Provided a framework for screening and validating APE-1 inhibitors.
Conclusions:
- APE-1 is a promising target for overcoming cancer drug resistance.
- The described purification and assay protocols are essential for identifying selective APE-1 inhibitors.
- These methods will accelerate the development of synergistic chemotherapeutic agents.
